An interventional study of iPAWS and Educational Materials in Pain, Postoperative and Substance Use, sponsored by Brown University. Recruiting at 1 site in United States. Open to participants aged 15 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Brown University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.
Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 236th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 68 that started in 2026, is one of 373 with no phase, reaches primary completion later than 80 of the 236 other live ones, and was the 1,156th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Columbia University · Sites in United States
Ages 12–21
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Women only
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 15 Years to 20 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 156 · Phase 3 179 · Phase 4 359
First in 1996; this study’s year is marked. 68 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 1,099 interventional studies, 130 across the 82 observational. Of the 784 that completed or were terminated, 475 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
200 of 1,181 have an industry lead sponsor. The 10 most frequent:
Brown University is the lead sponsor of 290 studies on the registry; 40 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 19 (73%) have results posted.
Brown University has 2 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
98 of the studies in Pain, Postoperative with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060495Phase 3Rutgers, The State University of New JerseyRADA16 for Adult Tonsillectomy | 2026-12-01 |
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,181 studies in Pain, Postoperative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical trial that will evaluate the feasibility and acceptability of a virtual brief program for adolescents and young adults undergoing wisdom tooth extraction and their parents. The program aims to teach youth safe and effective ways to manage post-surgical pain as well as decrease risky health behaviors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
*Endorse cannabis use at least two days per week on average in the past 28 days
*The investigator aims to recruit at least 50 participants who are using cannabis at least two days per week in the past 28 days on average and will recruit up to 100 additional participants who use other substances, use cannabis at a lesser intensity, or do not use any substances.
Exclusion Criteria:
- N/A
Participants in the experimental condition will receive standard practice educational materials and the iPAWS self-guided, digital intervention.
Behavioral: iPAWS · Other: Educational Materials
Participants in the control condition will receive standard practice educational materials (i.e., in the form of a brochure).
Other: Educational Materials
The brief intervention (named iPAWS) will be an integration of evidence-based brief interventions for AYA SU (e.g. MET-CBT) and acute pain coping (CBT). The intervention is brief, readily accessible, developmentally tailored, applicable to single and poly-SU and scalable to other acutely painful procedures to meet the need for effective, accessible, and scalable SU interventions at key entry points of clinical care.
Participants will be given a digital copy of a brochure from the American Dental Association on "Wisdom Teeth Management" (included in attachments). The investigator will also mail the participant a hard copy of the brochure, if requested.
Number of participants who complete the active treatment phase (feasibility)
The number of participants who complete the active treatment phase will determine feasibility. The treatment will be considered feasible if the number of participants who complete treatment is ≥ 70%.
Time frame: End of active treatment phase (6 weeks)
Number of participants who rate their treatment experience in the "satisfactory" or "highly satisfactory" range on the Client Satisfaction Questionnaire (Acceptability)
The Client Satisfaction Questionnaire (CSQ-8) which ranges in scores from 8 to 32 will determine acceptability. Higher scores indicate higher satisfaction (i.e. better outcomes). Treatment will be considered acceptable if the number and percentage of participants who rate their experience either "satisfactory" or "highly satisfactory is ≥ 80%.
Time frame: End of active treatment phase (6 weeks)
Number of cannabis use days
Number of days that participants consumed cannabis over the last 3 weeks (weeks 4-6 of treatment) will be measured by the Timeline Followback Interview.
Time frame: Last 3 weeks of active treatment phase (weeks 4-6)
Pain intensity
Average pain intensity is assessed during daily Ecological Momentary Assessments using the Numerical Rating Scale (NRS) . This is assessed on a scale from 0 (no pain) to 10 (most pain possible). Minimum value= 0 and maximum value=10. Higher scores indicate higher levels of pain (i.e. worse outcome). Analysis will examine average pain levels after treatment (weeks 4-6).
Time frame: Last 3 weeks of active treatment phase (weeks 4-6)
Substance use craving
Substance use craving is measured during daily Ecological Momentary Assessments using an item validated in past work: "How strong is your urge to use substances right now? This includes marijuana, alcohol, nicotine, and other drugs." This is assessed on scale from 0 (no urge) to 10 (strongest urge ever). Minimum value= 0 and maximum value=10 and higher scores indicate higher levels of craving (i.e. worse outcomes). Analysis will examine responses to this item after treatment (weeks 4-6).
Time frame: Last 3 weeks of active treatment phase (weeks 4-6)
Abstinent days
Abstinent days (proportion of days on which no cannabis use is reported) during the last 3 weeks (treatment weeks 4-6). The analysis will control for baseline (defined as proportion of abstinent days in the two weeks preceding the treatment).
Time frame: Last 3 weeks of active treatment phase (weeks 4-6)
Pain intereference
Pain interference is assessed during daily Ecological Momentary Assessments using 1 item: "How much is physical pain getting in the way of doing regular daily activities right now, including eating and drinking?" This is assessed on a scale from 0 (not at all ) to 10 (extremely). Minimum value= 0 and maximum value=10. Higher scores indicate higher levels of pain interference (i.e. worse outcome). Analysis will examine ratings of pain interference after treatment (weeks 4-6).
Time frame: Last 3 weeks of active treatment phase (weeks 4-6)
Pain coping strategies
Utilization of non-pharmacological pain coping skills is assessed during daily Ecological Momentary Assessments using a checklist of psychosocial (n=10 items) and physical coping strategies (n=10 items). Responses are binary (yes or no). The minimum value for each type of skill is 0 and the maximum value is 10. Higher scores reflect higher utilization of these skills (i.e. better outcomes). Analysis will examine utilization of non-pharmacological pain coping skills after treatment (weeks 4-6)
Time frame: Last 3 weeks of active treatment phase (weeks 4-6)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.